Who is sponsoring NCT01741311?

NCT01741311 is sponsored by University of Connecticut.

What condition does NCT01741311 study?

NCT01741311 studies Risk Behavior, Medication Adherence, HIV.

What drugs are being tested in NCT01741311?

Interventions: 3H+ (Holistic Health for HIV), HHRP+ (Holistic Health Recovery Program).

What is the status of NCT01741311?

NCT01741311 is currently COMPLETED.

Last reviewed 2025-08-06 · How we verify

Secondary HIV Prevention and Adherence Among HIV-infected Drug Users

NCT01741311 NA COMPLETED Results posted

This study will test whether 3H+ (Holistic Health for HIV) is comparable to the original HHRP+ (Holistic Health Recovery Program) in reducing HIV risk behaviors and improving ART (Antiretroviral Therapy) adherence in a randomized controlled comparative effectiveness trial among 256 HIV+ persons in drug treatment who report unsafe injection drug use practices or sexual risk behavior.

Details

Lead sponsor	University of Connecticut
Phase	NA
Status	COMPLETED
Enrolment	106
Start date	2012-09
Completion	2018-06

Conditions

Risk Behavior
Medication Adherence
HIV

Interventions

3H+ (Holistic Health for HIV)
HHRP+ (Holistic Health Recovery Program)

Primary outcomes

Number of Participants in Each Condition With Optimal ART Adherence — Assessed at post-intervention, 3-months, & 6-months. Reported in the table at 6-months.
Anti-retroviral therapy (ART) adherence was assessed by self-report using the visual analogue scale (VAS). The VAS measures adherence continuously from 0 to 100%, with higher scores indicating better adherence to the medication. A greater number of participants with optimal ART adherence is better. Optimal ART adherence is defined as a score \>95% on the visual analog scale (VAS).

Countries

United States